Long QT syndrome is the prototypical disorder of ventricular repolarization (VR), and a genotype-phenotype relation is postulated. Furthermore, although increased VR heterogeneity (dispersion) may be important in the arrhythmogenicity in long QT syndrome, this hypothesis has not been evaluated in humans and cannot be tested by conventional electrocardiography. In contrast, vectorcardiography allows assessment of VR heterogeneity and is more sensitive to VR alterations than electrocardiography. Therefore, vectorcardiography was used to compare the electrophysiological phenotypes of two mutations in the LQT1 gene with different in vitro biophysical properties, and with LQT2 mutation carriers and healthy control subjects. We included 99 LQT1 gene mutation carriers (57 Y111C, 42 R518X) and 19 LQT2 gene mutation carriers. Potassium channel function is in vitro most severely impaired in Y111C. The control group consisted of 121 healthy subjects. QRS, QT, and T-peak to T-end (Tp-e) intervals, measures of the QRS vector and T vector and their relationship, and T-loop morphology parameters were compared at rest. Apart from a longer heart rate-corrected QT interval (QT heart rate corrected according to Bazett) in Y111C mutation carriers, there were no significant differences between the two LQT1 mutations. No signs of increased VR heterogeneity were observed among the LQT1 and LQT2 mutation carriers. QT heart rate corrected according to Bazett and T p-e were longer, and the Tp-eto-QT ratio greater in LQT2 than in LQT1 and the control group. In conclusion, there was a marked discrepancy between in vitro potassium channel function and in vivo electrophysiological properties in these two LQT1 mutations. Together with previous observations of the relatively low risk for clinical events in Y111C mutation carriers, our results indicate need for cautiousness in predicting in vivo electrophysiological properties and the propensity for clinical events based on in vitro assessment of ion channel function alone.
mias, which typically take the morphological characteristics of Torsades des Pointes (TdP) polymorphic ventricular tachycardia, which can cause palpitations and syncope and degenerate into ventricular fibrillation and cause cardiac arrest or sudden death. A combination of LQTS type, age, sex, and symptoms is presently used, together with the electrocardiogram (ECG)-derived QT interval, to clinically stratify risk (15) . However, the ECG-derived QT interval may vary considerably within and between mutation carriers. Furthermore, the mutation type, location of the mutation within the channel protein, and biophysical effects on its function has tentatively been linked to the phenotype (13) .
Type 1 LQTS (LQT1), the most common form of LQTS, is due to mutations in the KNCQ1 gene. This gene encodes the potassium channel protein responsible for I Ks , the slow component of the delayed rectifying (repolarizing) current. The KCNH2 gene encodes the potassium channel protein responsible for I Kr , the rapid component of the delayed rectifier, and mutations in this gene cause type 2 LQTS (LQT2). Together, LQT1 and LQT2 constitute the vast majority of all LQT syndromes; they each reduce the repolarization reserve (17) , but impaired function in one of these potassium currents can at least partly be compensated for by the other.
Our laboratory has previously demonstrated that vectorcardiographic (VCG) recordings based on the Frank (X, Y, Z) lead system provide QT measurements that have greater diagnostic precision in individuals affected with LQTS than manual and automatic measurement in the standard 12-lead ECG (6, 7) . Furthermore, VCG has proven more sensitive to VR alterations than conventional ECG in human studies of cardiac memory development, whether induced by ventricular pacing or following Wolff-Parkinson-White ablation (31, 32) . VCG provides information about other aspects of VR in addition to its duration. Increased VR heterogeneity (hereafter termed VR dispersion) may be an important factor in arrhythmogenicity in LQTS (16, 20) . With VCG, it is possible to assess, for example, the spatial ventricular gradient (VG) [synonymously: QRST area (QRST area ) and QRST integral], which reflects the dispersion of action potential morphology (8, 10) , as well as VR dispersion reflected by T area (spatial area formed by the moving heart vector during the JT interval) and T amplitude (amplitude of the maximum T vector in space) (14) . Other properties of the three-dimensional (3D) T-vector loop, which presumably also reflect VR dispersion, such as its roundness and aplanarity (bulginess), are also easily assessed by VCG (14, 18, 31) . We, therefore, hypothesized that VCG would disclose other clinically relevant VR properties, in addition to prolongation of the QT interval in LQTS mutation carriers.
Two founder mutations in the Swedish population, R518X and Y111C in the KCNQ1 gene, account for ϳ25% of the mutations in the Swedish LQTS population (25, 33, 35) . According to in vitro studies, they have significantly different biophysical properties (24) . The primary aim of this study was, therefore, to compare the electrophysiological phenotypes in carriers of these two common mutations (24) . In addition, KCNQ1 mutation carriers were compared with age-and sexmatched healthy control subjects, as well as with a small group of genetically heterogeneous LQT2 mutation carriers.
Glossary

HR
Heart rate.
QRS amplitude
Amplitude of the maximum QRS vector in space.
QRS area
The spatial area formed by the moving heart vector during the QJ interval.
QRS-T angle
The angle between the maximum QRS and T vectors.
QRS-T area angle
The angle between the QRS area vector and the T area vector. QTcB and QTcF QT HR corrected according to Bazett and Fridericia, respectively. SD Standard deviation. T amplitude Amplitude of the maximum T vector in space.
T area
The spatial area formed by the moving heart vector during the JT interval.
T avplan
The mean distance between the periphery of the T loop and both sides of the preferential plane. T azimuth
The angle of the maximum T vector in the transverse plane (0°left, ϩ90°f ront, Ϫ90°back, and 180°right). T eigenvalue The squared quotient between the two largest perpendicular axes (eigenvalues) of the T loop in the preferential plane (d1/d2) 2 (where d1 Ն d2).
T elevation
The angle of the maximum T vector in the cranio-caudal direction by us defined from 0°(caudal direction) to 180°(cranial direction). T p-e T peak to T end, the last part of the QT interval and final repolarization. VCG Vectorcardiography. VG Ventricular gradient or QRST area is the spatial area formed by the moving heart vector during the QT interval. VR Ventricular repolarization. 3D Three-dimensional.
METHODS
This study included 150 individuals from 22 LQT1 families and 74 healthy volunteers. DNA from all members of the LQTS families was analyzed; no DNA analysis was performed in the healthy volunteers. All LQTS families were recruited from the LQTS family clinic; healthy volunteers were recruited from the hospital staff at Umeå University Hospital and their families.
The population consisted of 102 genetically confirmed KCNQ1 mutation carriers (60 Y111C and 42 R518X carriers); 3 children younger than 1 yr of age were excluded from the analysis (3 Y111C).
Additionally, 48 noncarrier family members (i.e., without the LQTS causing mutation) and 74 healthy volunteers unrelated to the LQTS families were age and sex matched to the mutation carriers; one child (noncarrier) younger than 1 yr of age was excluded from the analysis.
The healthy volunteers met the following inclusion criteria: 1) no history of sudden, unexpected death in any first-degree relative Ͻ40 yr of age; 2) no medication; and 3) no acute or chronic disease. Thus healthy volunteers were a complement to healthy noncarrier family members. Because LQT2 mutation carriers (in contrast to LQT1 mutation carriers) experience symptoms at rest, we also included 19 available adult LQT2 mutation carriers (22) .
This study was conducted in accordance with the Helsinki Declaration (2000) for Ethical Principles for Medical Research Involving Human Subjects and approved by the Regional Ethical Review board at Umeå University (Umeå, Sweden; ethical approval Dnr 05-127M). Written, informed consent was obtained from all subjects or their respective legal guardians.
VCG Recordings and Analyses
VCG was recorded by one person in all subjects at rest in the supine position, after at least 5 min of rest. Eight electrodes were applied: five around the chest at the level where the fourth intercostal space meets the sternum, one in the neck, one on the left hip, and one zero point on the right hip according to the Frank orthogonal lead system (X, Y, and Z). Recordings were performed using a CoroNet II system (Ortivus AB, Danderyd, Sweden) (9) . VCG was recorded continuously for 3-4 min and sampled in periods of 60 s for averaging for analysis of spatially (3D) based QRST intervals, as well as QRS and T vector and T vector loop (hereafter referred to as T loop) parameters. Signals from the three orthogonal leads X, Y, and Z were sampled at 500 Hz with an amplifier bandwidth of 0.03 to 170 Hz.
VCG analysis was performed as described in detail elsewhere, and the same terminology and definitions of parameters were used (19, 27, 32) . All parameters were analyzed offline at the University of Gothenburg using customized software. The averaged 3D QRST complex was used to assess the conventional QRS, QT, and T-peak to T-end (T p-e) intervals (ms) from which the Tp-e-to-QT ratio (Tp-e/QT) was calculated. The QT interval was heart rate (HR) corrected according to Bazett as QTcB ϭ QT/(RR) 1/2 and according to Fridericia as QTcF ϭ QT/(RR) 1/3 (RR in s). Because we observed no important differences between the QTcB and the QTcF, only QTcB are reported, except for subjects younger than 17 yr of age.
In addition, QRSarea (spatial area formed by the moving heart vector during the QJ interval), and Tarea (Vs), which are the spatial areas between the baseline and the curve formed by the moving vector during the QJ and JT intervals, respectively, were computed from the QRST complex in the three orthogonal directions: QRSarea 1/2 . The QRS-T area angle was defined as the angle between the QRSarea vector and the Tarea vector (0°to 180°).
The amplitude of the maximum QRS vector (mV) and T vector (mV) in space were defined as well as their relation (i.e., the QRS-T angle, 0°to 180°). Generally, the abnormality of these angles increases with width; however, there is a wide range of normality, as well as a gray zone, between "normal" and "abnormal" (37) . The spatial orientation of the maximum T vector was defined by its azimuth and elevation. Tazimuth is the angle in the transverse plane (0°l eft, ϩ90°front, Ϫ90°back, and 180°right). Televation is the angle in the cranio-caudal direction, defined by us from 0°(caudal direction) to 180°(cranial direction). The human T loop is normally elongated (elliptical) and located in one ("preferential") plane in space with the maximum vector pointing forward, downward, and to the left. The preferential plane was computed for each individual, and the T loop was characterized by two parameters: T eigenvalue [roundness; squared quotient between the two largest perpendicular axes (eigenvalues) of the T loop in the preferential plane; unitless] and T avplan (bulginess; mean distance between the periphery of the T loop and both sides of the preferential plane; V). T eigenvalue was computed as the squared quotient between the two largest perpendicular axes (eigenvalues) of the T loop in this plane (d1/d2) 2 (where d1 Ն d2). The T loop has a high Teigenvalue in a healthy individual, but can never have a more abnormal value than 1, for the special case of a circle. The third axis perpendicular to d1 and d2 is normally close to zero and was, therefore, disregarded in the computation of T eigenvalue, but is reflected by Tavplan. This parameter was computed as the mean distance between the periphery of the T loop and both sides of the preferential plane. T avplan reflects the loop's lack of planarity, while higher values represent a more bulgy and abnormal T loop (18) . At any instant, the T-vector value reflects the VR dispersion, and increases in T avplan are due either to a larger T vector or to a larger variation in its direction on both sides of the preferential plane during VR.
Genetic Analysis
Sequence analysis was performed in probands. In family members, targeted mutation analysis was performed as previously described (7).
Statistical Analysis
Descriptive data are presented as means Ϯ SD. Between-group comparisons were performed using the two-sided Mann-Whitney U-test and/or unpaired t-test. P values Ͻ 0.05 were considered statistically significant and presented to three decimal places.
RESULTS
In this section, we focus on the mutation carriers and control subjects Ն17 yr. Additional information is provided in the APPENDIX.
Clinical Characteristics
Clinical parameters were based on a questionnaire completed by the index persons and their family members and careful examination of hospital records. Data are summarized in Table 1 .
Among the 75 adult LQT1 mutation carriers, one patient (Y111C) had aborted cardiac arrest, while 22 more reported syncopal episodes of which 13 were of suspected arrhythmogenic origin and 9 of unclear cause. Two of the 19 LQT2 mutation carriers had aborted cardiac arrest, 2 more syncopal attacks and documented ventricular tachycardia, and 6 more syncopal attacks of which 2 were suspected to be due to arrhythmia.
Beta-blocking therapy was received by 56 LQT1 and LQT2 mutation carriers (47%), who had been on this therapy for at least 2 mo at the time of study; 48% took metoprolol, 32% propranolol, 11% atenolol, and 9% bisoprolol. A majority (14 of 24; 58%) of the younger mutation carriers (all LQT1) received beta-blocking therapy, mostly with propranolol.
VCG Analysis
Comparison of LQTS mutation carriers. Table 2 details the number of subjects, age, and sex for the different groups in this analysis, and Table 3 shows the results. The two KCNQ1 mutations differed significantly but modestly with regard to QTcB (Y111C vs. R518X: 460 Ϯ 26 vs. 446 Ϯ 33 ms; P ϭ 0.02). The difference was slightly larger in men than in women (446 Ϯ 24 vs. 418 Ϯ 14 ms; P ϭ 0.01), although women had longer QTcB intervals (472 Ϯ 21 vs. 455 Ϯ 32 ms; P ϭ 0.05).
(When other methods for HR correction of the QT interval were used, Fridericia, Hodges, and Framingham, there was no significant difference between the two LQT1 mutations; see also DISCUSSION). Among women, there were also significant differences in the QRS duration and T elevation , both of which were greater in R518X carriers. There were no differences in any other VR measures.
The only significant electrophysiological difference between the 23 symptomatic vs. the 52 asymptomatic LQT1 mutation carriers was a longer QT interval (454 Ϯ 47 vs. 430 Ϯ 39 ms; P ϭ 0.037).
When a comparison was made between all 75 LQT1 and 19 LQT2 mutation carriers, QTcB, T p-e , and T p-e /QT were signif- icantly larger in LQT2 carriers (two-sided Mann-Whitney U-test). In contrast, QRS duration, QRS amplitude, T area , T amplitude , T azimuth , QRS-T angle, QRS-T area angle, and VG were significantly greater in LQT1 carriers. In simplified terms, although the duration of VR (QTcB) and the final part of VR (T p-e /QT) were longer in LQT2 carriers, two VR dispersion measures (T area , T amplitude ) were greater in LQT1 carriers (although within a generally normal range; Table 4 ). LQT1 mutation carriers vs. control subjects. Comparisons between the 75 LQT1 mutation carriers and the 78 controls are shown in Table 5 . There were no differences in mean HR (66 Ϯ 11 vs. 67 Ϯ 11 beats/min; nonsignificant). Mean QT and QTcB intervals were significantly longer in LQT1 subjects (P Ͻ 0.000; unpaired t-test), as was the T p-e interval (P Ͻ 0.000).
LQT1 subjects had a wider angle between the QRS and T forces (P Յ 0.001), and the T vector was oriented more in the anterior direction (P Ͻ 0.001). The QRS amplitude and area were larger among controls (P Ͻ 0.001 and P ϭ 0.016, respectively).
Notably, there were no signs of increased VR or action potential dispersion among LQT1 subjects (see T area , T amplitude , T avplan , and VG; Table 5 ). In fact, T amplitude , VG, and T avplan were all significantly larger in controls (P ϭ 0.022, P ϭ 0.030, and P ϭ 0.012, respectively). There was an inverse relationship between QTcB and VG, T area , and T amplitude in both subjects with LQT1 and LQT2 (Fig. 1, A-C) and controls (Fig. 1, D-F) .
When comparing female and male LQT1 carriers vs. controls, there were more significant differences among women than among men; however, some differences were small and might represent spurious significances (Table 5 ). There were also significant sex-related differences among the control subjects (see APPENDIX Table A1 ). The results of the comparison of mutation carriers vs. control subjects 1-16 yr old are presented in the APPENDIX, including Table A2 .
DISCUSSION
Clinical risk assessment in patients with congenital LQTS is presently based on LQTS type, age, sex, symptoms, and QT interval (15) , but the role of specific mutations is attracting increasing attention (13) . In this study, two Swedish LQT1 founder mutations (Y111C and R518X) with considerably different biophysical ion channel properties, according to in vitro studies (24) , were compared. Apart from a longer QTcB interval in Y111C mutation carriers, there were no significant electrophysiological differences between the two LQT1 muta- 
Values are means Ϯ SD; n, no. of subjects. See text for definition of acronyms. *Significant between-group differences (P Ͻ 0.05; see text for specific P values). tions, demonstrating a large disparity between in vitro channel function and in vivo electrophysiological properties. Noninvasive electrophysiological assessment was performed applying 3D VCG, which allows both measurement of standard ECG intervals and, e.g., assessment of VR dispersion, which is thought to play a significant role in arrhythmogenesis in LQTS (16, 20) , but cannot be assessed reliably from the standard surface ECG (23) . When LQT1 mutation carriers were compared with age-and sex-matched healthy control subjects, we did not observe any significant increase in VCG measures of global VR dispersion (T p-e , T p-e /QT, T area ) or action potential morphology dispersion (VG ϭ QRST area ϭ QRST integral), although other VR measures differed significantly, as expected. Furthermore, the LQT1 mutation carriers were compared with a small group of LQT2 carriers, who had longer QTcB and T p-e and a greater T p-e /QT than LQT1 carriers, suggesting higher risk at rest, although VR dispersion measures were not larger in LQT2 carriers compared with controls subjects. Values are mean Ϯ SD; n, no. of subjects. See text for definition of acronyms. *Significant between-group differences (P Ͻ 0.05; see text for specific P values). Fig. 1 . There are inverse relations between QT heart rate corrected according to Bazett (QTcB) and ventricular gradient (VG), Tarea (spatial area formed by the moving heart vector during the JT interval), and Tamplitude (amplitude of the maximum T vector in space) in type 1 long QT (LQT1) and type 2 long QT (LQT2) mutation carriers (A-C; P Ͻ 0.000 for all) and controls (D-F; P Ͻ 0.000 for all).
LQT1 Mutations: In Vitro and In Vivo
The two LQT1 mutations compared in this study are located at different ends of the channel protein: Y111C at the NH 2 -terminus and R518X at the COOH-terminus. They are also considered to have different effects on the I Ks channel function (5, 34) . Y111C is a point mutation with a dominant-negative effect, which means that there is a Ͼ50% reduction of channel function (13) , and, according to functional studies, Ͼ75% reduction in the in vitro setting (5, 34) . R518X is a nonsense mutation whose functional effect is classified as haplo-insufficiency, meaning a Յ50% reduction of channel function. A rather modest difference in QTcB was the only consistent difference (Y111C vs. R518X: 460 Ϯ 26 vs. 446 Ϯ 33 ms; P ϭ 0.02). When HR correction was performed according to Fridericia, Hodges, and Framingham there was no significant difference between the two mutations. However, the QTc values obtained after applying these three methods (QTcF, QTcH, QTcFram, respectively) still showed a significant relation with HR. This was not the case for QTcB, which suggests that QTcB, at least in this study group, is the superior method for HR correction.
Moss et al. (13) observed significantly longer QT intervals (in line with our results) and more frequent cardiac events among 187 subjects with dominant-negative vs. 169 subjects with haplo-insufficiency mutations. A first cardiac event was observed more often in subjects with missense mutations and mutations located in the transmembrane part of the protein than in those without missense and COOH-terminally located mutations; there were very few NH 2 -terminal mutations. Of note, there was substantial colinearity for transmembrane mutations, missense mutations, and mutations with dominant-negative effects on the biophysical channel function in that study. Therefore, their individual effects could not be separated (13) . Importantly, Winbo et al. (34) showed that, compared with the general LQT1 population, Y111C mutation carriers in Sweden had a low incidence of life-threatening cardiac events and, therefore, a much better prognosis than expected, given its in vitro effect on channel function. This finding might indicate the presence of modifying factors in carriers of this founder mutation (33) , and/or that impaired in vitro biophysical channel function can be compensated for in vivo as an example of physiological redundancy, here expressed as retained repolarization reserve.
Our results were obtained at rest. Any other difference in ion channel function between the two LQT1 mutations than a modestly prolonged VR duration might not become apparent until the response to HR increase or catecholamines are assessed, which requires additional studies.
A crucial issue in this effect comparison of different LQT1 mutations is the sensitivity of VR analysis by VCG. The comparison between female and male controls at least partly answers this question. There were more and larger sex-related VR differences within the control group than between carriers of the two LQT1 mutations (Tables 1 and 4; APPENDIX Table  A1 ). Furthermore, according to a recent reproducibility study of 50 adult individuals, the coefficients of variation for interval-based parameters were Յ8%, and for most vector based parameters Յ20% (L. Bergfeldt, unpublished observations). Therefore, the power of the present study is sufficient to detect any meaningful differences between the two mutations at rest.
The results of the present and previous (34) studies thus show a large discrepancy between in vitro biophysical properties of the channel function in the Y111C LQT1 mutation in relation to in vivo electrophysiological properties and the occurrence of clinical events. This does not mean that the location and biophysical function of specific mutations have no implications for the in vivo function and the risk for clinical events. The results, however, caution from drawing conclusions about the clinical effects based on in vitro studies alone.
Dispersion of VR
Although the role of early and delayed afterdepolarizations in initiating TdP ventricular tachycardias is generally accepted, the role of VR dispersion is less clear: "Long QT syndrome patients may have greater-than-normal dispersion of refractoriness ..." (12) . Although we observed clear differences in QTcB, we did not observe any signs of increased dispersion of action potential morphology or VR in LQT1 or LQT2 mutation carriers (Fig. 2, A-C) . Because both VG and T area are rate dependent and decrease with increasing HR, the lack of difference in HR between the groups is of note (Fig. 2D) (26) . This result is in agreement with in vitro studies using optical mapping in the Langendorff preparation of hearts from the transgenic rabbit model of LQT1 (3). In the same study, the authors observed an increased dispersion of action potential durations across the anterior epicardial surface in four LQT2 rabbit hearts and linked this finding to arrhythmia occurrence. We observed a larger T p-e in LQT2 mutation carriers than in LQT1 carriers (and a numerically larger T p-e than in controls), which, according to the same in vitro study (3) , might fit with the LQT2 rabbit heart model. However, in our LQTS material (both LQT1 and LQT2), there was no correlation between T p-e and VG or T area , which (at least on theoretical grounds) may reflect dispersion of action potential morphology and VR, respectively (8, 10, 29) . However, there was a weak correlation between T p-e and QTcB (Fig. 3) . In contrast, among both LQT1 and LQT2 carriers, as well as among control subjects, there was actually an inverse relation between QTcB and VG, T area , and T amplitude (Fig. 1) . This novel information suggests that there is no permanent arrhythmia substrate (at rest) with increased dispersion of action potential morphology or increased global VR dispersion in LQT1, owing to the R518X and Y111C mutations. The absence of signs of increased VR dispersion at rest does not, however, mean that dispersion does not play a role in arrhythmogenesis in LQTS. It may evolve as a consequence of ␤-adrenergic stimulation (see also next paragraph). Furthermore, in healthy individuals, VG is rate dependent and decreases with increasing HR, while the relationship between T p-e and QT (T p-e /QT) remains constant (27) . The VR responses to HR increase and sympathetic nervous activation in LQT1 and LQT2 mutation carriers each deserve further study by VCG.
At least in LQT1, syncope or sudden death is triggered mostly by emotional or physical stress (22) , and QT interval prolongation may be especially notable during or after exercise or epinephrine challenge (30) . Additionally, phys-ical exercise and emotional stress were the most common triggers for syncopal episodes in Y111C mutation carriers (34) . In fact, even in healthy individuals, a transient paradoxical QT prolongation and delayed HR adaptation of T area and VG results from ␤-adrenergic stimulation after muscarinic blockade with atropine (28) . Whether such responses are more prominent in LQTS mutation carriers and can be used to identify patients at risk for malignant arrhythmias warrants further study. T p-e /QT has been proposed as an index for arrhythmogenicity, and a value of 0.28 has been suggested as a good cut-off point for TdP risk (11, 36) . In our study, T p-e /QT was significantly greater in LQT2 mutation carriers than in LQT1 mutation carriers (0.24 Ϯ 0.07 vs. 0.19 Ϯ 0.03, P ϭ 0.000). In fact, Ͼ25% (5 of 19) had a T p-e /QT Ͼ0.28, while only one of LQT1 mutation carrier reached this value. This finding might reflect that syncope or sudden death in LQT2 can occur even at rest (3, 22) . There was a correlation between T p-e and QT when taking all adult LQT1 and LQT2 mutation carriers and the controls together (r ϭ 0.44, r 2 ϭ 0.19; P Ͻ 0.000). Furthermore, in a recent study applying beat-to-beat analysis, our laboratory showed that the longer the QT interval, the larger was its instantaneous instability and also the instability of T area and VG (26) . Compared with age-and sex-matched controls, the instability was more than doubled. An increased instability of most aspects of VR thus seemed to be a salient feature of both LQT1 and LQT2 and may play an important role in the propensity for arrhythmia development. This needs further study.
Sex-Related Differences
A recent study reports that both sex-specific and mutationspecific information might be useful for risk assessment in LQT1 (4). Clearly, there were sex-related differences within the subgroups of mutation carriers (Tables 3 and 4) . However, there were also significant differences between men and women in the control group (APPENDIX), which emphasizes the Fig. 2 . Although there were differences in QTcB (A), there were no signs of increased heterogeneity of action potential morphology (B; VG), or increased dispersion of ventricular repolarization assessed by Tarea among the mutation carriers (C). D: there was no significant difference in heart rate between the groups. Genotype 0, control group; genotype 1, LQT1 mutation carriers; genotype 2, LQT2 mutation carriers. bpm, Beats/min. Fig. 3 . There was no correlation between T-peak to T-end (Tpeak-end) and VG (A; P ϭ 0.40), or between Tpeak-end and Tarea (B; P ϭ 0.85); however, a weak correlation was apparent between Tpeak-end and QTcB (C; P ϭ 0.002).
importance of sex-related and age-related analyses in this context.
Limitations and Methodological Aspects
A limitation of this study is that VR was only studied at supine rest during steady state. On the other hand, the LQT1 group was unusually homogeneous, consisting of two mutations and sufficiently large groups to allow detection of differences. Furthermore, analysis was performed on averaged cardiac cycles during short sampling periods, thus smoothing out any difference in beat-to-beat variability, which warrants additional study.
The LQT2 group was genetically more heterogeneous and consisted of only 19 adults. They were included because they have a condition with a higher likelihood of events at rest than LQT1 carriers, and in fact had more severe events than the entire LQT1 cohort. Results were quite consistent when comparing all LQT1 and LQT2 carriers, as when using an age-and sex-matched LQT1 group of the same size.
Conclusions
There was a marked discrepancy between in vitro potassium channel function and in vivo electrophysiological properties in these two LQT1 mutations. Together with previous observations of the relatively low risk for clinical events in Y111C mutation carriers, our results caution from predicting in vivo electrophysiological properties and the propensity for clinical events based on in vitro assessment of ion channel function alone.
APPENDIX
Statistical Analysis
In addition to addressing the main purposes of the study, we analyzed the influence of previously known factors affecting VR, including age, sex, LQT1 mutation, and beta-blocking therapy, by applying regression analyses. Because there was a strong relationship (linear or nonlinear) between age and most VR parameters, we divided all subjects in two groups: Ն17 yr of age were considered "adults", and below were considered "children". In the second step, healthy volunteers and family members who were not mutation carriers were compared on the assumption that there would be no difference, and that together they could serve as controls. In the third step, simple linear regression was used to compare LQT1 mutation carriers with controls. Finally, the results of all analyses depended strongly on both age and biological sex. Therefore, between-group comparisons were performed that took both of these factors into account using the Mann-Whitney U-test and/or unpaired t-test. P values Ͻ0.05 were considered statistically significant and presented to three decimal places.
General Analyses
Age, sex, and the presence of a mutation significantly affected most VR parameters. In contrast, beta-blocking therapy only affected the QT interval (decrease of ϳ16 ms), without affecting HR-corrected QT or other VR measures. These results motivated the separate analyses, taking into account age and sex, as presented in the main paper and below.
For the analysis of measured VCG parameters, we divided the population into two groups: adults Ն17 yr of age included 47 Y111C carriers (26 women), 28 R518X carriers (21 women), and 78 age-and sex-matched controls (48 women); children 1-16 yr of age included 10 Y111C carriers (6 girls), 14 R518X carriers (7 girls), and 43 controls (23 girls). In addition, 19 adult LQT2 mutation carriers were included (11 women). There was no significant difference between the two subgroups (noncarrier healthy family members and healthy volunteers); thus they were combined to constitute the control group (Table A1) .
Children 1-16 yr of Age
This group consisted of 24 mutation carriers: 4 were probands, 2 had experienced syncope, and 14 received beta-blocker therapy. Data analysis was performed in the undivided LQT1 population vs. control subjects (n ϭ 43). The QT and QTcB intervals were significantly longer in LQT1 mutation carriers (respectively: 382 Ϯ 47 vs. 349 Ϯ 39 m, P ϭ 0.009; 450 Ϯ 30 vs. 406 Ϯ 21 ms, P Ͻ 0.000), while the Tp-e/QT was larger in controls (0.17 Ϯ 0.02 vs. 0.19 Ϯ 0.02, P ϭ 0.000; Table A2 ). 
